Sign in
Taking people in United StatesPhase 1/2

CX-011 injected into the knee for painful knee osteoarthritis

Tests CX-011 injected into the knee joint for knee osteoarthritis pain.

Key facts

Who runs it
CarthroniX, Inc.
Where
Los Angeles, United StatesSee the site
Trial code
Registry title
Evaluation of Intra-articular CX-011 to Treat Moderate to Severe Pain From Knee Osteoarthritis
Status
Recruiting
Phase
Phase 1/2
People taking part
72 people, planned
Started
11 Aug 2026
Expected to end
31 Dec 2028
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • CX-011
Record updated
26 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe pain from knee osteoarthritis that other treatments did not relieve enough. They will get CX-011 or placebo injected into the knee.

Age
40 years up to less than 75 years
Sex
Men and women
Disease stage
Osteoarthritis of the knee seen on X-ray, Kellgren-Lawrence grade II or III. Symptoms for more than 3 months and pain on more than 15 days in the last month. VAS pain score of 4-8 out of 10 and WOMAC pain score of 11 or more out of 20. Body mass index under 40 kg/m2.
Earlier treatment
People must not have had enough relief, for at least 6 months in the last 12 months, from at least three osteoarthritis therapies. At least two must be drug treatments, such as painkillers, NSAIDS, steroid or hyaluronic acid injections. People cannot join after a steroid knee injection within 3 months, extended-release steroids within 4 months, or knee surgery within 12 months. GLP-1RA drugs are allowed only at a stable dose for at least 12 weeks.
Biomarker or test result
hsCRP ≥ 2 mg/L (a blood test for inflammation)

Main reasons for not taking part

  • Other types of arthritis, such as rheumatoid arthritis or psoriatic arthritis
  • Daily use of a cane or walker, or an unstable knee
  • Cannot have an MRI scan
  • HbA1c ≥ 8% (64 mmol/mol) or diabetes needing insulin
  • Pregnancy, breastfeeding, active cancer, or serious infections

The registry criteria, word for word

Show all 53 criteriaShow less

Who can take part

  • Written consent to participate in the study
  • Males or females 40 years of age or less than 75 years old
  • Diagnosis OA of the index knee by a combination of clinical and radiographic findings wherein the index knee is self-identified by the subject as the more severe knee (if both knees qualified) and symptoms have persisted for >3 months
  • Radiographic evidence of OA in the tibiofemoral compartment of the index knee (Kellgren-Lawrence grades II or III) within 6 months prior to Screening or during the Screening period
  • Index knee pain on most days (>15 days) over the last month
  • Subjects who have failed to adequately respond for at least 6 months within the previous 12 months to at least three osteoarthritis therapies that include at least two pharmacological treatments such as simple analgesics (e.g., acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS)), corticosteroid injection, extended-release steroid use within 4 months, Viscosupplement (e.g., hyaluronic acid) injection, platelet-rich plasma injection, bone marrow aspiration concentrate, placental-derived tissue/cells, adipose tissue, or any other autologous or allogeneic product. Conservative, non-pharmacological therapy includes: avoidance of activities that cause joint pain; exercise; weight loss; physical therapy; and removal of excess fluid from the knee
  • VAS Pain score of 4-8 on a 0 - 10 scale
  • Overall index knee pain score of 11 or more in the index knee using the 0 - 20 WOMAC Pain scale
  • hsCRP ≥ 2 mg/L
  • Body mass index < 40 kg/m2
  • If female, must not be pregnant or nursing and willing to refrain from becoming pregnant during the study
  • Willing to agree not to use illicit drugs during the study, including cannabinoids, and to have illicit drug testing at screening and at later time points if illicit drug use is suspected during the study
  • Able to comply with study requirements and complete the full sequence of protocol-related procedures and evaluations
  • Subjects shall agree to refrain from taking NSAIDS, opioids, intra-articular steroids and hyaluronic acid (viscosupplementation), electrotherapy and acupuncture during the study
  • Subjects receiving glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, liraglutide, dulaglutide, or tirzepatide, may be enrolled only if they have been on a stable maintenance dose for at least 12 weeks prior to screening, with no dose adjustments, and are not undergoing dose titration or escalation
  • Subjects shall agree to refrain from using topical pain therapies including capsaicin, lidocaine patches, heat patches, CBD oil and topical NSAIDs
  • Subjects shall agree to refrain from any additional pain medication for 24 h prior to all study visits, excluding screening visit
  • Male or female subjects with reproductive potential agree to comply with a highly effective contraceptive method from the first Screening visit through 90 days after last study drug administration. A highly effective method of contraception is defined as one that has no higher than a 1% failure rate. In this study, the only acceptable methods of contraception are as follows:; Hormonal contraception and male condom. ii. Placement of intrauterine system and male condom. iii. Female subject's partner vasectomized for ≥6 months prior to Screening and subject's verbal confirmation that absence of sperm in the ejaculate was confirmed; Female subject or male subject's partner with bilateral tubal ligation ≥6 months prior to Screening; Sexual abstinence when in relation to the preferred and usual lifestyle of the subject; Contraception requirements do not apply for subjects in an exclusively same-sex relationship. Subjects with reproductive potential who are not currently sexually active must agree to use acceptable contraception as specified above if they become sexually active during the study period and for 90 days after the last dose of study drug. Subjects with reproductive potential must agree not to donate sperm or eggs during the study and for 90 days after the last dose of study drug; Subjects are considered of non-reproductive potential if any of the following apply:; Post-menopausal female with ≥12 consecutive months of spontaneous amenorrhea with follicle stimulating hormone (FSH) >30 mIU/mL at Screening; Surgically sterile female and at least 6 weeks post-sterilization (i.e., bilateral oophorectomy or hysterectomy); Sterilized male ≥6 months post vasectomy and subject's verbal confirmation that absence of sperm in the ejaculate was confirmed
  • Prior to dosing on Day 1, subjects must meet the following criteria:; BP systolic between 90-160 mmHg and diastolic between 60-100 mmHg ii. Pulse between 60-100 bpm iii. Respiratory Rate between 12-20 per minute iv. Afebrile

Who cannot take part

  • Corticosteroid injection into the index knee within 3 months prior to screening; extended-release steroid use within 4 months prior to screening
  • Knee surgery or procedure on the index knee within 12 months prior to screening and/or planned knee surgery during the study including cold or radiofrequency nerve ablation
  • Knee surgery or procedure on the contralateral knee within 6 months prior to screening and/or planned knee surgery during the study including cold or radiofrequency nerve ablation
  • Acute index knee trauma within 3 months prior to screening
  • Current therapy with any immunosuppressive therapy, including corticosteroids (> 5 mg/day of prednisone) or subjects with conditions that would likely include treatment with immunosuppressive therapy (including corticosteroids) during the study period
  • Initiation of GLP-1RA therapy, dose titration or escalation, switching between GLP-1RA agents or discontinuation of GLP-1RA therapy within 12 weeks prior to screening or planned during the study period
  • Active use of moderate to strong inhibitors or inducers of major P450s
  • Systolic BP > 160 mmHg or diastolic BP > 100 mmHg or on > 3 blood pressure medications at screening
  • Participation in another clinical trial within the previous 30 days before screening or planned participation in another clinical trial during the study
  • Positive drug or alcohol screen
  • History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis or amyloidosis
  • Inability to undergo Magnetic Resonance Imaging (MRI) due to presence of surgical hardware or other foreign body in the index knee, or because of subject's claustrophobia or other MRI contraindication, including intolerance of or allergic reaction to IV contrast
  • Knee joint infections, skin diseases or infections in the area of the injection site
  • Moderate to severe renal impairment
  • Moderate to severe hepatic impairment
  • Clinically significant intercurrent illness, medical condition, non-knee pain, or medical history (including neurological or mental illness, human immunodeficiency virus, autoimmune diseases or connective tissue disorder, fibromyalgia, complex regional pain syndrome, clinical anxiety, clinical depression, any active infection including hepatitis B or C) that would jeopardize subject safety, limit participation, or compromise interpretation of data derived from the subject
  • X-ray showing any exclusionary criteria such as subchondral insufficiency fracture, tumor, osteonecrosis, fragmentation or collapse of part of the joint, infiltration of the bone marrow, stress fracture or reaction
  • History of active malignancy, with the exception of resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ within 5 years
  • Known active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral or parasitic infections, or ocular herpes simplex
  • Any infection requiring intravenous antibiotics within 4 weeks of Screening, infection requiring oral antibiotics within 2 weeks of Screening, history of chronic infection, or a history of osteomyelitis
  • Active psychiatric disorder including psychosis and major depressive disorder
  • History of or active Cushing's syndrome
  • Any other clinically significant acute or chronic medical conditions (e.g., uncontrolled diabetes) that, in the judgment of the Investigator, would preclude the use of CX-011 or that could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study
  • Viscosupplement (e.g., hyaluronic acid [HA] injection, platelet-rich plasma injection, bone marrow aspirate or bone marrow aspiration concentrate, placental-derived tissue/cells, adipose tissue, or any other autologous or allogeneic product) into the index knee within 3 months prior to screening
  • HbA1c ≥ 8% and/or insulin-dependent diabetes
  • Clinically significant findings on physical examination or screening tests (e.g. laboratory and radiographic) that are not specific to OA of the knee and may interfere with study conduct or interpretation of data or increase subject risk
  • Screening 12-lead electrocardiogram (ECG) consistently demonstrating heart rate corrected QT intervals (QTc) >450 msec in male subjects and >470 msec in female subjects or any clinically significant ECG abnormality as judged by the Investigator
  • Daily use of assistive devices (e.g. cane or walker) or presence of comorbidities that would limit the subject's ability to walk
  • Unstable joint (such as a torn anterior cruciate ligament)
  • Regular daily use of anticoagulants
  • VAS Pain score of ≥4 on a 0 - 10 scale in the contralateral knee
  • Symptoms of locking, intermittent block to range of motion, or loose body sensation that could indicate meniscal displacement or an IA loose body; knee ligament instability at the index knee
  • Major dysplasia or congenital abnormalities
  • Known intention to start any anti-obesity pharmacotherapy (including GLP-1RAs) during the study period

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 75 years old?

Where in United States

  • University of Southern CaliforniaLos Angeles, United StatesContact: Pui YanTaking people

About the trial

What the trial wants to find out

Study is designed to evaluate the safety and effectiveness of a drug called CX-011 to treat pain in patients with osteoarthritis of the knee. Osteoarthritis produces pain in the knee (and other joints) that typically is worsened by activities such as long distance walking and is alleviated by rest.

The 4 groups in the trial

  • PlaceboPlacebo, for comparison

    Treatment: CX-011

  • CX-011 low doseTreatment being tested

    Treatment: CX-011

  • CX-011 medium doseTreatment being tested

    Treatment: CX-011

  • CX-011 high doseTreatment being tested

    Treatment: CX-011

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1/2a Study to Evaluate the Safety and Tolerability Intra-articular CX-011 to Treat Moderate to Severe Pain From Knee Osteoarthritis
Plain-language title
CX-011 injected into the knee for painful knee osteoarthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07308834, who can take part
Record updated
26 August 2026